Literature DB >> 26718586

The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases.

Thea van den Bosch1, Alexander Boichenko2, Niek G J Leus1, Maria E Ourailidou1, Hannah Wapenaar1, Dante Rotili3, Antonello Mai4, Axel Imhof5, Rainer Bischoff2, Hidde J Haisma1, Frank J Dekker6.   

Abstract

Lysine acetylations are reversible posttranslational modifications of histone and non-histone proteins that play important regulatory roles in signal transduction cascades and gene expression. Lysine acetylations are regulated by histone acetyltransferases as writers and histone deacetylases as erasers. Because of their role in signal transduction cascades, these enzymes are important players in inflammation. Therefore, histone acetyltransferase inhibitors could reduce inflammatory responses. Among the few histone acetyltransferase inhibitors described, C646 is one of the most potent (Ki of 0.4μM for histone acetyltransferase p300). C646 was described to affect the NF-κB pathway; an important pathway in inflammatory responses, which is regulated by acetylation. This pathway has been implicated in asthma and COPD. Therefore, we hypothesized that via regulation of the NF-κB signaling pathway, C646 can inhibit pro-inflammatory gene expression, and have potential for the treatment of inflammatory lung diseases. In line with this, we demonstrate here that C646 reduces pro-inflammatory gene expression in RAW264.7 murine macrophages and murine precision-cut lung slices. To unravel its effects on cellular substrates we applied mass spectrometry and found, counterintuitively, a slight increase in acetylation of histone H3. Based on this finding, and structural features of C646, we presumed inhibitory activity of C646 on histone deacetylases, and indeed found inhibition of histone deacetylases from 7μM and higher concentrations. This indicates that C646 has potential for further development towards applications in the treatment of inflammation, however, its newly discovered lack of selectivity at higher concentrations needs to be taken into account.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acetylation; C646; C646 (PubChemCID: 1285941); Histones; Inflammation; Macrophages; NF-κB; SAHA (PubChemCID: 5311)

Mesh:

Substances:

Year:  2015        PMID: 26718586      PMCID: PMC4871277          DOI: 10.1016/j.bcp.2015.12.010

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  39 in total

Review 1.  Structure and function of histone acetyltransferases.

Authors:  R Marmorstein
Journal:  Cell Mol Life Sci       Date:  2001-05       Impact factor: 9.261

Review 2.  Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases.

Authors:  Frank J Dekker; Thea van den Bosch; Nathaniel I Martin
Journal:  Drug Discov Today       Date:  2013-11-21       Impact factor: 7.851

3.  Analysis of histone modifications by mass spectrometry.

Authors:  Ana Villar-Garea; Lars Israel; Axel Imhof
Journal:  Curr Protoc Protein Sci       Date:  2008-02

4.  Analysis of Histone Modifications from Tryptic Peptides of Deuteroacetylated Isoforms.

Authors:  Elisabeth Hersman; Dwella M Nelson; Wendell P Griffith; Christine Jelinek; Robert J Cotter
Journal:  Int J Mass Spectrom       Date:  2012-02-15       Impact factor: 1.986

Review 5.  Emerging approaches for histone deacetylase inhibitor drug discovery.

Authors:  Clemens Zwergel; Sergio Valente; Claus Jacob; Antonello Mai
Journal:  Expert Opin Drug Discov       Date:  2015-04-20       Impact factor: 6.098

6.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

Authors:  Ivan V Gregoretti; Yun-Mi Lee; Holly V Goodson
Journal:  J Mol Biol       Date:  2004-04-16       Impact factor: 5.469

7.  Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD.

Authors:  A Di Stefano; G Caramori; T Oates; A Capelli; M Lusuardi; I Gnemmi; F Ioli; K F Chung; C F Donner; P J Barnes; I M Adcock
Journal:  Eur Respir J       Date:  2002-09       Impact factor: 16.671

8.  Enzyme kinetics and inhibition of histone acetyltransferase KAT8.

Authors:  Hannah Wapenaar; Petra E van der Wouden; Matthew R Groves; Dante Rotili; Antonello Mai; Frank J Dekker
Journal:  Eur J Med Chem       Date:  2015-10-22       Impact factor: 6.514

9.  A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.

Authors:  Xiao-ning Gao; Ji Lin; Qiao-yang Ning; Li Gao; Yu-shi Yao; Ji-hao Zhou; Yong-hui Li; Li-li Wang; Li Yu
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

10.  Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3/H4.

Authors:  Ryan A Henry; Yin-Ming Kuo; Andrew J Andrews
Journal:  Biochemistry       Date:  2013-08-12       Impact factor: 3.162

View more
  16 in total

Review 1.  The inflammatory effect of epigenetic factors and modifications in type 2 diabetes.

Authors:  Mohamad Akbari; Vahideh Hassan-Zadeh
Journal:  Inflammopharmacology       Date:  2019-11-09       Impact factor: 4.473

2.  Developmental Control of NRAMP1 (SLC11A1) Expression in Professional Phagocytes.

Authors:  Mathieu F M Cellier
Journal:  Biology (Basel)       Date:  2017-05-03

3.  Photoelectrochemical determination of the activity of histone acetyltransferase and inhibitor screening by using MoS2 nanosheets.

Authors:  Huanshun Yin; Hanwen Wu; Yan Chen; Fei Li; Jun Wang; Shiyun Ai
Journal:  Mikrochim Acta       Date:  2019-08-31       Impact factor: 5.833

4.  Effects of the histone acetylase inhibitor C646 on growth and differentiation of adipose-derived stem cells.

Authors:  Zhimin Wang; Xiao Wang; Meiyu Bi; Xiao Hu; Qing Wang; Hao Liang; Dongjun Liu
Journal:  Cell Cycle       Date:  2021-01-25       Impact factor: 4.534

Review 5.  Role of Epigenetics in the Regulation of Immune Functions of the Skin.

Authors:  Yu Sawada; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2020-11-27       Impact factor: 8.551

6.  A 6-alkylsalicylate histone acetyltransferase inhibitor inhibits histone acetylation and pro-inflammatory gene expression in murine precision-cut lung slices.

Authors:  Thea van den Bosch; Niek G J Leus; Hannah Wapenaar; Alexander Boichenko; Jos Hermans; Rainer Bischoff; Hidde J Haisma; Frank J Dekker
Journal:  Pulm Pharmacol Ther       Date:  2017-03-16       Impact factor: 3.282

7.  Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay.

Authors:  Xiaoming Bai; Hongmin Sun; Shuo Wu; Yuhuan Li; Lifei Wang; Bin Hong
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

8.  HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice.

Authors:  Niek G J Leus; Thea van den Bosch; Petra E van der Wouden; Kim Krist; Maria E Ourailidou; Nikolaos Eleftheriadis; Loes E M Kistemaker; Sophie Bos; Rutger A F Gjaltema; Solomon A Mekonnen; Rainer Bischoff; Reinoud Gosens; Hidde J Haisma; Frank J Dekker
Journal:  Sci Rep       Date:  2017-03-27       Impact factor: 4.379

Review 9.  The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target.

Authors:  Marta Di Martile; Donatella Del Bufalo; Daniela Trisciuoglio
Journal:  Oncotarget       Date:  2016-08-23

10.  Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases.

Authors:  Michael R Michaelides; Arthur Kluge; Michael Patane; John H Van Drie; Ce Wang; T Matthew Hansen; Roberto M Risi; Robert Mantei; Carmen Hertel; Kannan Karukurichi; Alexandre Nesterov; David McElligott; Peter de Vries; J William Langston; Philip A Cole; Ronen Marmorstein; Hong Liu; Loren Lasko; Kenneth D Bromberg; Albert Lai; Edward A Kesicki
Journal:  ACS Med Chem Lett       Date:  2017-12-13       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.